Prevention for LongevityInstitutionIntelligenceStandardWorkAboutDiscuss an opportunity

Evidence Explorer · EV-005

PROSPR

PROSPR funds seven teams to build healthspan measures and accelerated trials, with up to $144M over five years.

Primary/authoritativeCurrentFederal R&D program2026-02-24

What this evidence supports

PROSPR funds seven teams to build healthspan measures and accelerated trials, with up to $144M over five years.

What it does not establish

The seven awards and funding ceiling are program facts, not evidence that the full ceiling will be paid or that an endpoint or intervention works. Continued funding is milestone-contingent, and the work remains investigational.

Answer-ready summary

ARPA-H PROSPR is explicitly building biomarkers, trial methods, and therapeutics aimed at extending healthspan.

Record details

Decision priority
Watch
Current status
Seven program awards listed · up to $144M over five years · milestone-contingent
Evidence tracks
Measures/endpoints · Science/market
Source authority
Primary/authoritative
Source organization
ARPA-H
Evidence design
Federal R&D program
Applicability
Applicable to decisions about the stated program, policy, standard, or development context; not evidence of clinical benefit beyond the cited scope.
Confidence for the stated claim
High
Freshness
Current
Record date
2026-02-24
Source updated
2026-02-24
Last verified
2026-09-03
Review due
2026-10-03 or sooner if the cited source changes.
Version
1.1
Revision state
Version 1.1 records the September 3, 2026 re-verification, adds current PROSPR program and award-directory sources, and clarifies that the seven awards, funding ceiling, and continued funding are milestone-contingent rather than evidence of results.

Evidence record fields

Claim supported
PROSPR funds seven teams to build healthspan measures and accelerated trials, with up to $144M over five years.
Source type and design
Federal R&D program
Population and setting
Not a participant-level clinical-study population in this source type. The program, policy, regulatory, standards, or research context described by the cited source.
Intervention/exposure and comparator
Not evaluated as a comparative intervention or exposure in the cited administrative or program source. No comparator is reported for this source-bounded claim.
Outcome or endpoint
The program, policy, regulatory, standards, or development state stated in the claim supported; no clinical outcome is inferred.
Follow-up duration
No clinical follow-up duration is reported for this source-bounded claim.
Effect estimate and uncertainty
No clinical effect estimate is reported. No statistical uncertainty estimate is reported; uncertainty is bounded through the source scope and stated limitations.
Harms/adverse events
No harms or adverse-event analysis is reported for this source-bounded administrative or program claim.
Missing data and attrition
Not reported; this record does not analyze participant-level data. Not applicable or not reported; no longitudinal participant cohort is analyzed.
Bias/limitations
The seven awards and funding ceiling are program facts, not evidence that the full ceiling will be paid or that an endpoint or intervention works. Continued funding is milestone-contingent, and the work remains investigational.
Applicability/generalizability
Applicable to decisions about the stated program, policy, standard, or development context; not evidence of clinical benefit beyond the cited scope.
Funding/conflicts
Funding or sponsorship is recorded only where the cited source and claim state it; otherwise it is not assessed in this record. No conflict-of-interest assessment is reported for this administrative or program-source record.
Replication or corroboration
The administrative or program claim is anchored to the cited authoritative source; independent clinical replication is not implied.
Decision use
Use as source-bounded context for Researchers, Innovators, Funders/investors, Policymakers; do not use as stand-alone evidence of safety, efficacy, coverage, endorsement, or scaled adoption.
Last reviewed / review due
Last reviewed 2026-09-03; review due 2026-10-03 or sooner if the cited source changes.

For this decision

Researchers · Innovators · Funders/investors · Policymakers

Primary sources

Related intelligence